Predictors of antibody persistence to the 7-valent pneumococcal conjugate vaccine in healthy Fijian infants at 12 months of age. Issue 33 (14th July 2020)

• Record Type: Journal Article
• Authors: Lindholm, Daniel E.; Licciardi, Paul V.; Ratu, Felisita T.; Kim Mulholland, E.; Nguyen, Cattram D.; Russell, Fiona M.
• Is Part Of: Vaccine. Volume 38:Issue 33(2020)
• Page Start: 5095
• Page End: 5099
• Publication Date: 2020-07-14
• Subjects: Pneumococcal conjugate vaccine -- Poor antibody persistence -- Ethnicity -- Reduced-dose schedule -- Fiji -- Infant; PCV pneumococcal conjugate vaccine -- PCV7 7-valent pneumococcal conjugate vaccine -- RCT randomised control trial -- URTI upper respiratory tract infection -- IgG immunoglobulin G -- OI opsonophagocytic index -- aOR adjusted odds ratio -- HPV human papillomavirus vaccine -- CI confidence interval; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2020.06.025
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Little is known about the predictors of antibody persistence to pneumococcal conjugate vaccines (PCV) in the context of reduced dose schedules. In Fiji, an RCT investigated 0, 1, 2 and 3 dose schedules of 7-valent PCV administered at 6, 10 and 14 weeks of age in 364 healthy infants. This study was a post-hoc analysis of the predictors of poor antibody persistence at 12 months, prior to a booster, using univariable and multivariable analyses. The strongest predictors of poor antibody persistence as measured by serotype-specific immunoglobulin G (IgG) and opsonophagocytosis (OI) assays were being of Indigenous Fijian ethnicity (IgG: adjusted odds ratio (aOR) 3.43, p < 0.001; OI: aOR 1.96, p = 0.013) and receipt of fewer than 3 doses of PCV. These findings may help to identify which children may be at an increased risk of pneumococcal disease in the context of reduced dose primary series PCV schedules.